Postoperative atrial fibrillation (POAF) is expected to occur in up to 30% of patients undergoing coronary artery bypass surgery, in Ϸ50% after valvular surgery, and in 60% after combined coronary artery bypass surgery and valve surgery. 1 Recognition of the inflammatory process as a cause of POAF in cardiac surgery and the efficacy of colchicine in reducing postpericardiotomy syndrome 2 made colchicine a potential drug for POAF prophylaxis. Until the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy, the efficacy and safety of colchicine for the prevention of POAF had never been evaluated. The COPPS trial included 336 patients who were in sinus rhythm before they began the intervention. After baseline characteristics were adjusted for confounding factors, Imazio et al 3 established that colchicine led to a reduced incidence of POAF (12.0% versus 22.0%, PϽ0.021, with a number needed to treat of 11). Additionally, Imazio et al 3 established a shorter in-hospital stay and rehabilitation stay with colchicine treatment. It is not clear whether the favorable results of the COPPS POAF trial were caused by concomitant use of ␤-blockers, given that the hazard ratio for ␤-blockers in the study was 0.47 (nϭ174; 95% confidence interval, 0.25-0.88; PϽ0.019), with a hazard ratio of 0.52 for colchicine (nϭ169; 95% confidence interval, 0.28 -0.96; PϽ0.036).
